Evaluation of cardiac manifestations in pediatric liver transplant candidates

Pediatric Transplantation

Volumn 16, Issue 4, 2012, Pages 318-328

  Madan, Nitin ^a   Arnon, Ronen ^a,b   Arnon, Rica ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

cardiac; liver transplant; pediatric

Indexed keywords

TACROLIMUS;

ALAGILLE SYNDROME; ALPHA 1 ANTITRYPSIN DEFICIENCY; BILE DUCT ATRESIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHILDHOOD DISEASE; CONGESTIVE HEART FAILURE; CRIGLER NAJJAR SYNDROME; CYSTIC FIBROSIS; ELECTROCARDIOGRAM; END STAGE LIVER DISEASE; FALLOT TETRALOGY; FATTY ACID OXIDATION; FULMINANT HEPATIC FAILURE; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 3; GLYCOGEN STORAGE DISEASE TYPE 4; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONTRACTILITY; HEART REPOLARIZATION; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM DEFECT; HEMANGIOENDOTHELIOMA; HEMOCHROMATOSIS; HEPATOPULMONARY SYNDROME; HUMAN; HYPEROXALURIA; IMAGE ANALYSIS; IMMUNOSUPPRESSIVE TREATMENT; INFERIOR CAVA VEIN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG ANGIOGRAPHY; LUNG EDEMA; MAPLE SYRUP URINE DISEASE; OXALOSIS 1; OXYGENATION; PORTOPULMONARY HYPERTENSION; PROPIONIC ACIDEMIA; PULMONARY ARTERY STENOSIS; PULMONARY HYPERTENSION; PULMONARY VALVE STENOSIS; QT INTERVAL; REVIEW; SUDDEN DEATH; TYROSINEMIA; UREA CYCLE DISORDER; UREA NITROGEN BLOOD LEVEL; VASODILATATION; WILSON DISEASE;

ALAGILLE SYNDROME; BILIARY ATRESIA; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CHILD; END STAGE LIVER DISEASE; HEMANGIOENDOTHELIOMA; HEPATOPULMONARY SYNDROME; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LONG QT SYNDROME; METABOLISM, INBORN ERRORS;

EID: 84861187967     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2012.01667.x     Document Type: Review

References (118)

1. Johnston SD, Morris JK, Cramb R, et al., Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002: 73: 901-906. (Pubitemid 34252352)
2. Mandell MS, Lindenfeld J, Tsou MY, et al., Cardiac evaluation of liver transplant candidates. World J Gastroenterol 2008: 14: 3445-3451.
3. Raval Z, Harinstein ME, Skaro AI, et al., Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol 2011: 58: 223-231.
4. Al Hamoudi W, Lee SS,. Cirrhotic cardiomyopathy. Ann Hepatol 2006: 5: 132-139. (Pubitemid 44435349)
5. Therapondos G, Flapan AD, Plevris JN, et al., Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004: 10: 1441-1453. (Pubitemid 40028375)
6. Ozcay F, Tokel K, Varan B, et al., Cardiac evaluation of pediatric liver transplantation candidates. Transplant Proc 2002: 34: 2150-2152. (Pubitemid 35299698)
7. Desai MS, Zainuer S, Kennedy C, et al., Cardiac structural and functional alterations in infants and children with biliary atresia, listed for liver transplantation. Gastroenterology 2011: 141: 1264-1272.
8. Fewtrell MS, Noble-Jamieson G, Revell S, et al., Intrapulmonary shunting in the biliary atresia/polysplenia syndrome: Reversal after liver transplantation. Arch Dis Child 1994: 70: 501-504. (Pubitemid 24201066)
9. Tumgor G, Arikan C, Yuksekkaya HA, et al., Childhood cirrhosis, hepatopulmonary syndrome and liver transplantation. Pediatr Transplant 2008: 12: 353-357. (Pubitemid 351589443)
10. Noli K, Solomon M, Golding F, et al., Prevalence of hepatopulmonary syndrome in children. Pediatrics 2008: 121: e522-e527.
11. Rodriguez-Roisin R, Krowka MJ, Herve P, et al., Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004: 24: 861-880. (Pubitemid 39504442)
12. Schenk P, Schoniger-Hekele M, Fuhrmann V, et al., Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003: 125: 1042-1052. (Pubitemid 37193451)
13. Rodriguez-Roisin R, Krowka MJ,. Hepatopulmonary syndrome-A liver-induced lung vascular disorder. N Engl J Med 2008: 358: 2378-2387.
14. Willis AD, Miloh TA, Arnon R, et al., Hepatopulmonary syndrome in children-Is conventional liver transplantation always needed? Clin Transplant 2010: 25: 849-855.
15. Al-Hussaini A, Taylor RM, Samyn M, et al., Long-term outcome and management of hepatopulmonary syndrome in children. Pediatr Transplant 2010: 14: 276-282.
16. Arguedas MR, Abrams GA, Krowka MJ, et al., Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003: 37: 192-197. (Pubitemid 36042160)
17. Fishberger SB, Pittman NS, Rossi AF,. Prolongation of the QT interval in children with liver failure. Clin Cardiol 1999: 22: 658-660. (Pubitemid 29468283)
18. Arikan C, Kilic M, Tumgor G, et al., Impact of liver transplantation on rate-corrected QT interval and myocardial function in children with chronic liver disease. Pediatr Transplant 2009: 13: 300-306.
19. Bal JS, Thuluvath PJ,. Prolongation of QTc interval: Relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 2003: 23: 243-248. (Pubitemid 37265799)
20. Zambruni A, Trevisani F, Di Micoli A, et al., Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol 2008: 48: 415-421.
21. Kuo PC, Plotkin JS, Gaine S, et al., Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999: 67: 1087-1093. (Pubitemid 29205568)
22. Ridaura-Sanz C, Mejia-Hernandez C, Lopez-Corella E,. Portopulmonary hypertension in children. A study in pediatric autopsies. Arch Med Res 2009: 40: 635-639.
23. Whitworth JR, Ivy DD, Gralla J, et al., Pulmonary vascular complications in asymptomatic children with portal hypertension. J Pediatr Gastroenterol Nutr 2009: 49: 607-612.
24. Condino AA, Ivy DD, O'Connor JA, et al., Portopulmonary hypertension in pediatric patients. J Pediatr 2005: 147: 20-26. (Pubitemid 40981140)
25. Kawut SM, Taichman DB, Ahya VN, et al., Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005: 11: 1107-1111. (Pubitemid 41341761)
26. Swanson KL, Krowka MJ,. Screen for portopulmonary hypertension, especially in liver transplant candidates. Cleve Clin J Med 2008: 75: 121-136.
27. Laving A, Khanna A, Rubin L, et al., Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol. J Pediatr Gastroenterol Nutr 2005: 41: 466-468. (Pubitemid 41407610)
28. Iqbal CW, Krowka MJ, Pham TH, et al., Liver transplantation for pulmonary vascular complications of pediatric end-stage liver disease. J Pediatr Surg 2008: 43: 1813-1820.
29. Ashfaq M, Chinnakotla S, Rogers L, et al., The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007: 7: 1258-1264. (Pubitemid 46643089)
30. Schott R, Chaouat A, Launoy A, et al., Improvement of pulmonary hypertension after liver transplantation. Chest 1999: 115: 1748-1749. (Pubitemid 29275676)
31. Shah T, Isaac J, Adams D, et al., Development of hepatopulmonary syndrome and portopulmonary hypertension in a paediatric liver transplant patient. Pediatr Transplant 2005: 9: 127-131. (Pubitemid 40238978)
32. Rafanan AL, Maurer J, Mehta AC, et al., Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000: 118: 1497-1500.
33. Yoon PW, Bresee JS, Olney RS, et al., Epidemiology of biliary atresia: A population-based study. Pediatrics 1997: 99: 376-382. (Pubitemid 27176009)
34. Chardot C, Carton M, Spire-Bendelac N, et al., Epidemiology of biliary atresia in France: A national study 1986-96. J Hepatol 1999: 31: 1006-1013.
35. Davenport M, Tizzard SA, Underhill J, et al., The biliary atresia splenic malformation syndrome: A 28-year single-center retrospective study. J Pediatr 2006: 149: 393-400. (Pubitemid 44291378)
36. Gilljam T, McCrindle BW, Smallhorn JF, et al., Outcomes of left atrial isomerism over a 28-year period at a single institution. J Am Coll Cardiol 2000: 36: 908-916.
37. Becker DJ, Islam S, Geiger JD,. Biliary atresia associated with hypoplastic left heart syndrome: A case report and review of the literature. J Pediatr Surg 2004: 39: 1411-1413. (Pubitemid 39186544)
38. Deveci MS, Deveci G,. Biliary atresia splenic malformation syndrome-Is it a result of embryonically midline rotational defects? A case report J Pediatr Surg 2000: 35: 1377-1380.
39. Hartley JL, Davenport M, Kelly DA,. Biliary atresia. Lancet 2009: 374: 1704-1713.
40. Peoples WM, Moller JH, Edwards JE,. Polysplenia: A review of 146 cases. Pediatr Cardiol 1983: 4: 129-137. (Pubitemid 13034597)
41. Barbe T, Losay J, Grimon G, et al., Pulmonary arteriovenous shunting in children with liver disease. J Pediatr 1995: 126: 571-579.
42. Gupta NA, Abramowsky C, Pillen T, et al., Pediatric hepatopulmonary syndrome is seen with polysplenia/interrupted inferior vena cava and without cirrhosis. Liver Transpl 2007: 13: 680-686. (Pubitemid 46796539)
43. Warthen DM, Moore EC, Kamath BM, et al., Jagged1 (JAG1) mutations in Alagille syndrome: Increasing the mutation detection rate. Hum Mutat 2006: 27: 436-443. (Pubitemid 43673330)
44. Englert C, Grabhorn E, Burdelski M, et al., Liver transplantation in children with Alagille syndrome: Indications and outcome. Pediatr Transplant 2006: 10: 154-158.
45. Arnon R, Annunziato R, Miloh T, et al., Orthotopic liver transplantation for children with Alagille syndrome. Pediatr Transplant 2010: 14: 622-628.
46. Emerick KM, Rand EB, Goldmuntz E, et al., Features of Alagille syndrome in 92 patients: Frequency and relation to prognosis. Hepatology 1999: 29: 822-829. (Pubitemid 29109597)
47. McElhinney DB, Krantz ID, Bason L, et al., Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation 2002: 106: 2567-2574. (Pubitemid 35340693)
48. Cheng KW, Huang JJ, Wang CH, et al., Anesthetic management of a patient with Alagille's syndrome undergoing living donor liver transplantation without blood transfusion. Chang Gung Med J 2004: 27: 449-453.
49. Arnon R, Kerkar N, Davis MK, et al., Liver transplantation in children with metabolic diseases: The studies of pediatric liver transplantation experience. Pediatr Transplant 2010: 14: 796-805.
50. Arnon R, Annunziato RA, Miloh T, et al., Liver and combined lung and liver transplantation for cystic fibrosis: Analysis of the UNOS database. Pediatr Transplant 2011: 15: 254-264.
51. Rovedder PM, Ziegler B, Pinotti AF, et al., Prevalence of pulmonary hypertension evaluated by Doppler echocardiography in a population of adolescent and adult patients with cystic fibrosis. J Bras Pneumol 2008: 34: 83-90.
52. Koelling TM, Dec GW, Ginns LC, et al., Left ventricular diastolic function in patients with advanced cystic fibrosis. Chest 2003: 123: 1488-1494. (Pubitemid 36549767)
53. Labombarda F, Pellissier A, Ellafi M, et al., Myocardial strain assessment in cystic fibrosis. J Am Soc Echocardiogr 2011: 24: 1037-1045.
54. Montgomery GS, Sagel SD, Taylor AL, et al., Effects of sildenafil on pulmonary hypertension and exercise tolerance in severe cystic fibrosis-related lung disease. Pediatr Pulmonol 2006: 41: 383-385.
55. Dormer RL, Harris CM, Clark Z, et al., Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005: 60: 55-59. (Pubitemid 40101019)
56. Markiewicz-Kijewska M, Szymczak M, Ismail H, et al., Liver transplantation for fulminant Wilson's disease in children. Ann Transplant 2008: 13: 28-31.
57. Karakayali H, Ekici Y, Ozcay F, et al., Pediatric liver transplantation for acute liver failure. Transplant Proc 2007: 39: 1157-1160. (Pubitemid 46764849)
58. Arnon R, Annunziato R, Schilsky M, et al., Liver transplantation for children with Wilson disease: Comparison of outcomes between children and adults. Clin Transplant 2011: 25: E52-E60.
59. Kuan P,. Cardiac Wilson's disease. Chest 1987: 91: 579-583. (Pubitemid 17058884)
60. Factor SM, Cho S, Sternlieb I, et al., The cardiomyopathy of Wilson's disease. Myocardial alterations in nine cases. Virchows Arch A Pathol Anat Histol 1982: 397: 301-311. (Pubitemid 13236320)
61. Hlubocka Z, Marecek Z, Linhart A, et al., Cardiac involvement in Wilson disease. J Inherit Metab Dis 2002: 25: 269-277. (Pubitemid 34987475)
62. Meenakshi-Sundaram S, Taly AB, Kamath V, et al., Autonomic dysfunction in Wilson's disease-A clinical and electrophysiological study. Clin Auton Res 2002: 12: 185-189. (Pubitemid 34994579)
63. Mohan N, McKiernan P, Preece MA, et al., Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999: 158 (Suppl 2): S49-S54.
64. Edwards MA, Green A, Colli A, et al., Tyrosinaemia type I and hypertrophic obstructive cardiomyopathy. Lancet 1987: 1: 1437-1438. (Pubitemid 17078895)
65. Arora N, Stumper O, Wright J, et al., Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis 2006: 29: 54-57.
66. Andre N, Roquelaure B, Jubin V, et al., Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I. J Inherit Metab Dis 2005: 28: 103-106.
67. Davis MK, Weinstein DA,. Liver transplantation in children with glycogen storage disease: Controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant 2008: 12: 137-145. (Pubitemid 351326916)
68. Koeberl DD, Kishnani PS, Chen YT,. Glycogen storage disease types I and II: Treatment updates. J Inherit Metab Dis 2007: 30: 159-164. (Pubitemid 46487996)
69. Coleman RA, Winter HS, Wolf B, et al., Glycogen debranching enzyme deficiency: Long-term study of serum enzyme activities and clinical features. J Inherit Metab Dis 1992: 15: 869-881. (Pubitemid 23023190)
70. Labrune P, Huguet P, Odievre M,. Cardiomyopathy in glycogen-storage disease type III: Clinical and echographic study of 18 patients. Pediatr Cardiol 1991: 12: 161-163.
71. Vertilus SM, Austin SL, Foster KS, et al., Echocardiographic manifestations of glycogen storage disease III: Increase in wall thickness and left ventricular mass over time. Genet Med 2010: 12: 413-423.
72. Lee PJ, Deanfield JE, Burch M, et al., Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III. Am J Cardiol 1997: 79: 834-838. (Pubitemid 27152354)
73. Miller CG, Alleyne GA, Brooks SE,. Gross cardiac involvement in glycogen storage disease type 3. Br Heart J 1972: 34: 862-864.
74. Tada H, Kurita T, Ohe T, et al., Glycogen storage disease type III associated with ventricular tachycardia. Am Heart J 1995: 130: 911-912.
75. Toyota H, Kurokawa S, Tanaka H, et al., Case of glycogenosis III with marked fibrosis of the myocardium and cardiac failure. Nihon Naika Gakkai Zasshi 1992: 81: 583.
76. Kishnani PS, Austin SL, Arn P, et al., Glycogen storage disease type III diagnosis and management guidelines. Genet Med 2010: 12: 446-463.
77. Moses SW, Parvari R,. The variable presentations of glycogen storage disease type IV: A review of clinical, enzymatic and molecular studies. Curr Mol Med 2002: 2: 177-188. (Pubitemid 34649839)
78. Nambu M, Kawabe K, Fukuda T, et al., A neonatal form of glycogen storage disease type IV. Neurology 2003: 61: 392-394. (Pubitemid 36975974)
79. Van Woerden CS, Groothoff JW, Wanders RJ, et al., Primary hyperoxaluria type 1 in the Netherlands: Prevalence and outcome. Nephrol Dial Transplant 2003: 18: 273-279. (Pubitemid 36181676)
80. Bergstralh EJ, Monico CG, Lieske JC, et al., Transplantation outcomes in primary hyperoxaluria. Am J Transplant 2010: 10: 2493-2501.
81. Palka P, Duhig E, Carey L, et al., Primary oxalosis with cardiac involvement: Echocardiographic features of an unusual form of cardiomyopathy. Circulation 2001: 103: E122-E123.
82. Van Driessche L, Dhondt A, De Sutter J,. Heart failure with mitral valve regurgitation due to primary hyperoxaluria type 1: Case report with review of the literature. Acta Cardiol 2007: 62: 202-206. (Pubitemid 46649240)
83. Quan KJ, Biblo LA,. Type I primary hyperoxaluria: An unusual presentation of ventricular tachycardia. Cardiol Rev 2003: 11: 318-319. (Pubitemid 37421070)
84. Mookadam F, Smith T, Jiamsripong P, et al., Cardiac abnormalities in primary hyperoxaluria. Circ J 2010: 74: 2403-2409.
85. Detry O, Honore P, Deroover A, et al., Reversal of oxalosis cardiomyopathy after combined liver and kidney transplantation. Transpl Int 2002: 15: 50-52. (Pubitemid 36055900)
86. Vara R, Turner C, Mundy H, et al., Liver transplantation for propionic acidemia in children. Liver Transpl 2011: 17: 661-667.
87. Baumgartner D, Scholl-Burgi S, Sass JO, et al., Prolonged QTc intervals and decreased left ventricular contractility in patients with propionic acidemia. J Pediatr 2007: 150: 192-197.
88. Romano S, Valayannopoulos V, Touati G, et al., Cardiomyopathies in propionic aciduria are reversible after liver transplantation. J Pediatr 2010: 156: 128-134.
89. Parini R, Menni F, Garavaglia B, et al., Acute, severe cardiomyopathy as main symptom of late-onset very long-chain acyl-coenzyme A dehydrogenase deficiency. Eur J Pediatr 1998: 157: 992-995. (Pubitemid 28559750)
90. Dyke PC Jr, Konczal L, Bartholomew D, et al., Acute dilated cardiomyopathy in a patient with deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase. Pediatr Cardiol 2009: 30: 523-526.
91. Marci M, Ajovalasit P,. Medium-chain acyl-CoA dehydrogenase deficiency in an infant with dilated cardiomyopathy. Cardiol Res Pract 2009: 2009: 281-389.
92. Spiekerkoetter U, Lindner M, Santer R, et al., Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: Results from a workshop. J Inherit Metab Dis 2009: 32: 488-497.
93. Pervaiz MA, Kendal F, Hegde M, et al., MCT oil-based diet reverses hypertrophic cardiomyopathy in a patient with very long chain acyl-coA dehydrogenase deficiency. Indian J Hum Genet 2011: 17: 29-32.
94. Isaacs H Jr,. Fetal and neonatal hepatic tumors. J Pediatr Surg 2007: 42: 1797-1803. (Pubitemid 350090027)
95. Mouat F, Evans HM, Cutfield WS, et al., Massive hepatic hemangioendothelioma and consumptive hypothyroidism. J Pediatr Endocrinol Metab 2008: 21: 701-703.
96. Balazs AE, Athanassaki I, Gunn SK, et al., Rapid resolution of consumptive hypothyroidism in a child with hepatic hemangioendothelioma following liver transplantation. Ann Clin Lab Sci 2007: 37: 280-284. (Pubitemid 47311348)
97. Selby DM, Stocker JT, Waclawiw MA, et al., Infantile hemangioendothelioma of the liver. Hepatology 1994: 20: 39-45. (Pubitemid 24196489)
98. Daller JA, Bueno J, Gutierrez J, et al., Hepatic hemangioendothelioma: Clinical experience and management strategy. J Pediatr Surg 1999: 34: 98-106. (Pubitemid 29047261)
99. Klein I, Ojamaa K,. Thyroid hormone and the cardiovascular system. N Engl J Med 2001: 344: 501-509. (Pubitemid 32164903)
100. Le Luyer B, Duquenoy A, Poinsot J, et al., Use of interferon in a case of hepatic hemangioma. Arch Pediatr 2000: 7: 1201-1204.
101. Woltering MC, Robben S, Egeler RM,. Hepatic hemangioendothelioma of infancy: Treatment with interferon alpha. J Pediatr Gastroenterol Nutr 1997: 24: 348-351. (Pubitemid 27199625)
102. Hurvitz SA, Hurvitz CH, Sloninsky L, et al., Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol 2000: 22: 527-532. (Pubitemid 33599828)
103. Sarialioglu F, Erbay A, Demir S,. Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-alpha therapy. Pediatr Blood Cancer 2010: 55: 1433-1434.
104. Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al., Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010: 157: 340-342.
105. Sciveres M, Marrone G, Pipitone S, et al., Successful first-line treatment with propranolol of multifocal infantile hepatic hemangioma with high-flow cardiac overload. J Pediatr Gastroenterol Nutr 2011: 53: 693-695.
106. Yeh I, Bruckner AL, Sanchez R, et al., Diffuse infantile hepatic hemangiomas: A report of four cases successfully managed with medical therapy. Pediatr Dermatol 2011: 28: 267-275.
107. Kullendorff CM, Cwikiel W, Sandstrom S,. Embolization of hepatic hemangiomas in infants. Eur J Pediatr Surg 2002: 12: 348-352. (Pubitemid 35434706)
108. Warmann S, Bertram H, Kardorff R, et al., Interventional treatment of infantile hepatic hemangioendothelioma. J Pediatr Surg 2003: 38: 1177-1181. (Pubitemid 37048037)
109. Fellows KE, Hoffer FA, Markowitz RI, et al., Multiple collaterals to hepatic infantile hemangioendotheliomas and arteriovenous malformations: Effect on embolization. Radiology 1991: 181: 813-818.
110. Fok TF, Chan MS, Metreweli C, et al., Hepatic haemangioendothelioma presenting with early heart failure in a newborn: Treatment with hepatic artery embolization and interferon. Acta Paediatr 1996: 85: 1373-1375. (Pubitemid 26382393)
111. Walsh R, Harrington J, Beneck D, et al., Congenital infantile hepatic hemangioendothelioma type II treated with orthotopic liver transplantation. J Pediatr Hematol Oncol 2004: 26: 121-123. (Pubitemid 38186272)
112. Grabhorn E, Richter A, Fischer L, et al., Neonates with severe infantile hepatic hemangioendothelioma: Limitations of liver transplantation. Pediatr Transplant 2009: 13: 560-564.
113. Dehghani SM, Haghighat M, Imanieh MH, et al., Tacrolimus related hypertrophic cardiomyopathy in liver transplant recipients. Arch Iran Med 2010: 13: 116-119.
114. Atkison P, Joubert G, Barron A, et al., Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995: 345: 894-896.
115. Chang RK, McDiarmid SV, Alejos JC, et al., Echocardiographic findings of hypertrophic cardiomyopathy in children after orthotopic liver transplantation. Pediatr Transplant 2001: 5: 187-191. (Pubitemid 32545265)
116. Jarzembowski TM, John E, Panaro F, et al., Reversal of tacrolimus-related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6-year-old recipient. Pediatr Transplant 2005: 9: 117-121. (Pubitemid 40238976)
117. Turska-Kmiec A, Jankowska I, Pawlowska J, et al., Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient. Pediatr Transplant 2007: 11: 319-323. (Pubitemid 46570139)
118. Sindhi R, Webber S, Venkataramanan R, et al., Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001: 72: 851-855. (Pubitemid 32879857)